MedTrace Logo

Routine Therapy Plus Moxifloxacin in Advanced Breast Cancer

NCT03405168 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2018-11-16

No results posted yet for this study

Summary

This is a phase II,single center,prospective, single arm clinical trial. The objective is to evaluate the efficacy and safety of routine therapy plus moxifloxacin in Advanced Breast Cancer whose evaluation is stable disease with a trend of progression.

Conditions

Interventions

DRUG

Moxifloxacin Hydrochloride 400mg Tablet

Moxifloxacin is oral administration, 400 mg once a day, D1 to D7, 28 days as one cycle.

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • jiajia huang · Sun-yatsen University Cancer center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2018-07-30
Completion
2018-07-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03405168 on ClinicalTrials.gov